| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 69,462 | 101,685 | 53,333 | 55,307 |
| Cost of product sales | 4,753 | 4,504 | 4,409 | 8,026 |
| Research and development | 7,353 | 6,821 | 8,436 | 6,182 |
| Selling, general and administrative | 28,936 | 29,257 | 27,715 | 27,043 |
| Total costs and expenses | 41,042 | 40,582 | 40,560 | 41,251 |
| Income from operations | 28,420 | 61,103 | 12,773 | 14,056 |
| Interest income | 1,094 | 753 | 591 | 425 |
| Interest expense | 1,894 | 1,874 | 1,853 | 2,060 |
| Income before income taxes | 27,620 | 59,982 | 11,511 | - |
| (benefit from) provision for income taxes | -280 | 369 | 65 | - |
| Net income | 27,900 | 59,613 | 11,446 | 12,421 |
| Earnings per share, basic | 1.55 | 3.33 | 0.64 | 0.71 |
| Earnings per share, diluted | 1.46 | 3.28 | 0.63 | 0.7 |
| Weighted-average common shares outstanding, basic | 18,038,000 | 17,885,000 | 17,808,000 | 17,600,000 |
| Weighted-average shares outstanding and common stock equivalents | 19,156,000 | 18,162,000 | 18,169,000 | 17,648,000 |
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)